VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research report sent to investors on Friday. The brokerage issued a sell rating on the stock.

Separately, Cantor Fitzgerald reissued an overweight rating and set a $2.50 target price on shares of VolitionRx in a research note on Thursday, May 16th.

VolitionRx Stock Performance

NYSE VNRX opened at $0.66 on Friday. The business has a 50 day simple moving average of $0.74 and a 200 day simple moving average of $0.84. VolitionRx has a 52-week low of $0.55 and a 52-week high of $1.58. The stock has a market cap of $54.78 million, a price-to-earnings ratio of -1.43 and a beta of 1.16.

VolitionRx (NYSE:VNRX) last posted its earnings results on Monday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.27 million. On average, analysts predict that VolitionRx will post -0.34 EPS for the current year.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC purchased a new position in shares of VolitionRx Limited (NYSE:VNRX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned approximately 0.19% of VolitionRx as of its most recent SEC filing. Institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.